Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dermata Therapeutics Inc
(NQ:
DRMA
)
1.690
UNCHANGED
Streaming Delayed Price
Updated: 10:55 AM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dermata Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
61 Biggest Movers From Yesterday
November 23, 2021
Gainers Longeveron Inc. (NASDAQ: LGVN) shares surged 181.2% to settle at $28.20 on Monday on continued upward momentum after the company last week announced the FDA granted Rare...
Via
Benzinga
Exposures
Product Safety
12 Health Care Stocks Moving In Monday's Intraday Session
November 22, 2021
Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 95.32% to $9.61 during Monday's regular session. Trading volume for iSpecimen's stock is 70.9 million as of...
Via
Benzinga
52 Biggest Movers From Friday
November 22, 2021
Gainers Greenland Technologies Holding Corporation (NASDAQ: GTEC) shares surged 90.2% to close at $9.89 on Friday. Greenland Technologies highlighted the launch of second...
Via
Benzinga
Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why
November 19, 2021
Dermata Therapeutics Inc (NASDAQ: DRMA) announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic...
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
November 19, 2021
Gainers SCYNEXIS (NASDAQ:SCYX) stock rose 15.69% to $7.15 during Friday's regular session. As of 12:30 EST, this security is trading at a volume of 1.2 million shares...
Via
Benzinga
Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions
November 19, 2021
- Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance - Duration of effect lasted approximately 3 months - No potential distant spread of toxin observed SAN...
From
Dermata Therapeutics
Via
AccessWire
The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial
November 19, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Connect Biopharma Atopic Dermatitis Treatment Aces Mid-stage Study But Lack...
Via
Benzinga
Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea
November 17, 2021
- Topline results expected in second half of 2022 - Rosacea affects about 16 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / November 17, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the...
From
Dermata Therapeutics
Via
AccessWire
Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update
November 15, 2021
- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - -...
From
Dermata Therapeutics
Via
AccessWire
Topics
Initial Public Offering
Exposures
Product Safety
Securities Market
The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More
November 14, 2021
Biotech stocks declined for the second straight week amid a broader market pullback, along with earnings news from small- and micro-cap companies and presentations at...
Via
Benzinga
Exposures
Product Safety
Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
November 12, 2021
SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and...
From
Dermata Therapeutics
Via
AccessWire
Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Conditions
November 11, 2021
SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and...
From
Dermata Therapeutics
Via
AccessWire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
October 19, 2021
Gainers Entasis Therapeutics Hldg (NASDAQ:ETTX) shares moved upwards by 16.72% to $3.63 during Tuesday's pre-market session. The company's market cap stands at $...
Via
Benzinga
18 Stocks Moving in Tuesday's Pre-Market Session
October 19, 2021
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 26.1% to $2.03 in pre-market trading after surging 18% on Monday. Kaival Brands Innovations recently announced...
Via
Benzinga
Dermata Stock Jumps On Positive Psoriasis Candidate Data
October 19, 2021
Dermata Therapeutics Inc (NASDAQ: DRMA) announced topline results from its Phase 1b trial of DMT310 for mild-to-moderate psoriasis. The percentage of treatment...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 18, 2021
Gainers Dermata Therapeutics (NASDAQ:DRMA
Via
Benzinga
Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psoriasis
October 18, 2021
- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 -...
From
Dermata Therapeutics
Via
AccessWire
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 29, 2021
Gainers NuCana (NASDAQ:NCNA) stock increased by 22.36% to $2.9 during Wednesday's regular session. The current volume of 77.9 million shares is 21650.59% of NuCana...
Via
Benzinga
The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug
September 30, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 29) Acceleron Pharma Inc. (...
Via
Benzinga
Exposures
COVID-19
Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update
September 27, 2021
- Completed oversubscribed $18 million Initial Public Offering (IPO) - - Set to announce topline results from its DMT310 Phase 1b proof of concept (POC) study in mild to moderate psoriasis in 4Q 2021 -...
From
Dermata Therapeutics
Via
AccessWire
Topics
Initial Public Offering
Intellectual Property
Exposures
Intellectual Property
Product Safety
Securities Market
50 Biggest Movers From Yesterday
September 23, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares jumped 61.9% to close at $9.21 on Wednesday following an announcement from management that the company entered into a...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 22, 2021
Gainers Regencell Bioscience (NASDAQ:
Via
Benzinga
32 Stocks Moving In Wednesday's Mid-Day Session
September 22, 2021
Gainers Marin Software Incorporated (NASDAQ: MRIN) shares climbed 53.1% to $8.71 following an announcement from management that the company entered into a revenue share...
Via
Benzinga
Why Are Dermata Therapeutics Shares Trading Higher Today?
September 21, 2021
Brookline has initiated Dermata Therapeutics Inc's (NASDAQ: DRMA) coverage with a Buy rating and $14 price target. Analyst Kumaraguru Raja sees an upside of...
Via
Benzinga
The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
September 21, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20) Cerevel Therapeutics...
Via
Benzinga
Exposures
COVID-19
Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting
September 21, 2021
The presentation will highlight efficacy and safety data from a Phase 1b proof of concept study evaluating one application of DMT410 as a new topical intradermal delivery mechanism of botulinum toxin...
From
Dermata Therapeutics
Via
AccessWire
48 Biggest Movers From Yesterday
September 21, 2021
Gainers Edesa Biotech, Inc. (NASDAQ: EDSA) shares climbed 102.7% to settle at $11.92 on Monday after the company disclosed Phase 2 data of its monoclonal antibody in hospitalized...
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
September 20, 2021
Gainers Atea Pharmaceuticals (NASDAQ:AVIR) shares increased by 13.83% to $29.86 during Monday's regular session. Trading volume for this security as of 12:30 EST is 3....
Via
Benzinga
The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
September 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 15) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout
September 14, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 13) Abbott Laboratories (NYSE...
Via
Benzinga
Exposures
COVID-19
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.